News | Mammography | November 21, 2018

Company will show off cloud-based quantitative breast imaging analysis tools, host speaker series

Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA

November 21, 2018 — Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. 25–30 in Chicago. Its suite of cloud-based quantitative breast imaging analysis tools is designed to help maintain consistent quality in breast screening.

This year, Volpara will launch the VolparaLive! system, mammography's first real-time decision support system at the point of care. The VolparaLive! system automatically analyzes patient positioning and compression to help technologists acquire consistent, high-quality mammograms. One of the key benefits of the system is the cost reduction of fewer technical recalls, made possible by providing technologists with actionable data before the patient leaves the room.

Major improvements to the VolparaEnterprise software will be demonstrated for the first time:

  • A new reporting function for periodic image quality reviews further streamlines Enhancing Quality Using the Inspection Program (EQUIP) compliance and the image quality review process;

  • Users can generate a list of exams based on the VolparaEnterprise quality assessment for periodic image quality reviews, sorting by interpreting physicians and technologists; and

  • The software now features vPGMI, a new image positioning quality standard, according to Volpara.

This year, Volpara will host a distinguished speaker series at RSNA, including:

  • Prof. Jack Cuzick: Volpara and Risk Assessment: Importance of Volumetric Density in TC8

    • Director, Wolfson Institute of Preventive Medicine; Head, Centre for Cancer Prevention and John Snow Professor of Epidemiology, Queen Mary University of London

  • JoAnn Pushkin: Breast Density Legislation and Education – US and Europe

    • Executive Director, DenseBreast-Info.org

  • Prof. Sir Mike Brady: How AI and Machine Learning Can Impact Mammography

    • Professor of Oncological Imaging, University of Oxford

  • Amy Chatten, MPH, Measuring the Impact of Hands-On Technologist Training on Mammographic Image Quality

    • Executive Director, Mammography Educators, LLC

 

For more information: www.volparasolutions.com


Related Content

News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
Subscribe Now